Q-Med Launches a Pharmaceutical in Sweden.STOCKHOLM, Sweden -- Q-Med (Nasdaq:QMED) (STO:QMED) hereby announces that a pharmaceutical, Cosmofer(R) (low molecular iron dextran iron dextran Cosmofer (UK), DexFerrum, InFeD Pharmacologic class: Trace element Therapeutic class: Iron supplement Pregnancy risk category C FDA Boxed Warning), has now been approved for sales in Sweden. It is estimated that sales will start towards the end of the year.Q-Med has an agreement with the Danish manufacturer Nebo/Pharmacosmos (www.pharmacosmos.com) concerning sales rights for the preparation on the Swedish market. Cosmofer is given through an infusion in a vein or as an injection in a muscle. What is unique for Cosmofer is that the patient's total need can be given in a single dose. The product is used for the treatment of serious iron deficiency iron deficiency A relative or absolute deficiency of iron which may be due to chelation in the GI tract, loss due to acute or chronic hemorrhage or dietary insufficiency Sources Meat, poultry, eggs, vegetables, cereals, especially if fortified with iron; per the where treatment with tablets is not tolerated or does not have sufficient effect. The need can be seen above all in people with kidney disease, in cancer patients, in cases of inflammatory intestinal disease, during pregnancy and in connection with surgical procedures when it is desirable to avoid blood transfusions. Q-Med has previous experience of intravenous iron and had sales of a similar preparation up until 1999. WHO estimates that approximately 3 billion people, more than 30% of the world's population, have anemia, above all due to iron deficiency. In Sweden there are 4 oral iron products, which together have sales of SEK SEK In currencies, this is the abbreviation for the Swedish Krona. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 28.5 million. Only one intravenous product exists today, Venofer, with sales of SEK 26.6 million during 2005. In the US, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc. Q-Med is a rapidly growing and profitable biotechnology/medical device company. The company develops, produces, markets and sells implants for esthetic and medical use. All products are based on the company's patented technology for the production of stabilized non-animal hyaluronic acid, NASHA NASHA Non-Animal, Stabilized Hyaluronic Acid (trademark of Q-Med AB; Uppsala, Sweden) NASHA National Association for Speech and Hearing Action (Rockville, MD) (TM). The product portfolio today contains: RESTYLANE, for the filling out of lips and facial wrinkles and for facial contouring; DUROLANE, for the treatment of osteoarthritis osteoarthritis or osteoarthrosis or degenerative joint disease Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. of the hip and knee joints; DEFLUX, for the treatment of vesicoureteral reflux (a malformation malformation /mal·for·ma·tion/ (-for-ma´shun) 1. a type of anomaly. 2. a morphologic defect of an organ or larger region of the body, resulting from an intrinsically abnormal developmental process. of the urinary bladder) in children and ZUIDEX, for the treatment of stress urinary incontinence stress urinary incontinence n. See stress incontinence. in women. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has just over 560 co-workers, with approximately 370 at the company's head office and production facility in Uppsala, Sweden. The Q-Med share is listed on the O-list of the Stockholm Stock Exchange The Stockholm Stock Exchange (Swedish: Stockholmsbörsen) is a stock exchange located in Stockholm, Sweden. Founded in 1863 [1] it is the primary securities exchange of the Nordic Countries. . www.q-med.com NASHA, DUROLANE, ZUIDEX, IMPLACER, DEFLUX and all product names within the RESTYLANE family are trademarks that belong to Q-Med. This information was brought to you by Waymaker http://www.waymaker.net |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion